Global Solid Tumor Summit

April 25 and 26, 2023

QIAGEN

Agenda

Day 1: Tuesday, April 25

Time (CET)	Session and speaker
13:00–13:15	**Opening remarks from QIAGEN**
13:15–14:00	**New frontiers in biomarker testing and cancer patient profiling** Prof. Umberto Malapelle, Department of Public Health, University Federico II of Naples, Naples, Italy
14:00–14:30	**Impact of molecular testing in patients with solid tumors** Dr. Ernest Nadal, Catalan Institute of Oncology (ICO), Duran i Reynals Hospital, Barcelona, Spain
14:30–15:00	**Expert panel discussion: From research to clinics — what's next for *KRAS*?** Prof. Malapelle, Dr. Nadal and Dr. Pascale Morel (QIAGEN)
15:00–15:30	**Coffee break**
15:30–16:10	**Biomarker testing in NSCLC** Prof. Tae-Jung Kim, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
16:10–16:40	**Thought leadership with Prof. Kim: Single biomarker testing vs multiple – a futuristic perspective for NSCLC** Prof. Tae-Jung Kim and Scott Markland (QIAGEN)
16:40–17:10	**Case study: resistance to first-line osimertinib in patients with *EGFR*-mutated NSCLC** Dr. Marc Denis, Plateforme de Génétique Moléculaire des Cancers, CHU - Hôtel-Dieu, Nantes, France
17:10–18:00	**Roundtable with patients: Access and perspective – advancing patient care** Dr. Marc Denis, Ms. Lisa Alderson (patient; UK), Dr. Egbert Schulze (MVZ Labor Dr. Limbach, Heidelberg, Germany) and Dr. Pascale Morel (QIAGEN)
18:00–18:10	**Closing remarks from QIAGEN**

Day 2: Wednesday, April 26

Time (CET)	Session and speaker
9:00–9:10	**Opening remarks from QIAGEN**
9:10–10:10	**Biomarker testing using digital PCR: Reaching new horizons in cancer diagnostics** Prof. Hsian-Rong Tseng, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, USA
10:10–10:50	**Roundtable discussion: Companion diagnostics for biomarker profiling – a pharma perspective** Ms. Lee-Anne Zinetti (Senior Director, Global Precision Medicine, Novartis) and Aaron Jordan (QIAGEN)
10:50–11:30	**Comprehensive genomic profiling to interrogate DNA alterations using next-generation sequencing** Dr. Laura Lahtinen, Keski-Suomen Sairaala Nova Patologia, Jyväskylä, Finland
11:30–13:30	**Lunch and networking**
13:30–14:40	**Using multimodal chemistry to test neurological tumor samples** Dr. Barnaby Clark, King's College Hospital, Denmark Hill, London, UK
14:40–15:20	**Expert panel: New horizons with digital PCR and NGS** Prof. Hsian-Rong Tseng, Dr. Laura Lahtinen, Dr. Barnaby Clark and Dr. Mehdi Motallebipour (QIAGEN)
15:20–15:30	**Closing remarks from QIAGEN**

Continuing Medical Education

QIAGEN is accredited by the American Association of Continuing Medical Education® to provide continuing medical education for physicians. The Accreditation Review Committee designates this educational activity for a maximum of 9.75 hours category I credits in the Association's Credit Designation. Each physician must claim only those credits that he/she actually spent in the educational activity.

It is the policy of the American Association of Continuing Medical Education® to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. All faculty participating in continuing medical education activities sponsored by QIAGEN are required to disclose to the program audience any real or apparent conflict of interest related to the content of their presentations. All faculty are also required to disclose any discussions of unlabeled/unapproved uses of drugs or devices.